2. Αποκάλυψη σύγκρουσης συμφερόντων
• Roche, AMGEN, BMS (honoraria)
• Novartis (consultancy)
[υποχρεωτική αποκάλυψη σύγκρουσης συμφερόντων για συμμετέχοντες στις
επιστημονικές εκδηλώσεις ομιλητές, σύμφωνα με την τροποποίηση της εγκυκλίου
του Ε.Ο.Φ. υπ’ αριθμ. 14660/25-2-2011, άρθρο 3, και την επανακοινοποίηση υπ’
αριθμ. 47558/4-7-2012]
3. Kirkwood JM et al, CA Cancer J Clin 2012; 62: 309-35.
Η ανοσοθεραπεία στην ογκολογία
8. Lawrence M. et al. Nature. 2013 Jul 11;499(7457):214-8.
Somatic mutation frequencies observed in exomes
form 3,083 tumor-normal pairs. Tumor types are
ordered by their median somatic mutation
frequency with the highest frequencies on the
right in tumors induced by carcinogens.
27. Patients Reporting Event, %
NIVO + IPI
(N = 313)
NIVO
(N = 313)
IPI
(N = 311)
Any
Grade
Grade
3–4
Any
Grade
Grade
3–4
Any
Grade
Grade
3–4
Treatment-related adverse event
(AE)
95.5 55.0 82.1 16.3 86.2 27.3
Treatment-related AE leading to
discontinuation
36.4 29.4 7.7 5.1 14.8 13.2
Treatment-related death* 0 0.3 0.3
*One reported in the NIVO group (neutropenia) and one in the IPI group (cardiac arrest).
• 67.5% of patients (81/120) who discontinued the NIVO + IPI combination
due to treatment-related AEs developed a response
IPI + NIVO: τοξικότητα
28. Data from Hodi et al, ASCO 2015, slide adapted from JJ Grob, EADO 2015
Immunotherapy combos
54% Gr3-4 toxicity
Severe, however
manageable
Earlier appearance
Tx interruption did
not compromise
efficacy!
35. cuSCC/KAs with vemurafenib
Left chest
KRASG12D
Chin
HRASQ61L
Left scalp
HRASQ61L
Torso
No RAS mutation
Normal Skin Normal SkincuSCC/KA cuSCC/KA
IHC staining for pERK (Roger Lo)
cuSCC/KA pictures and H&E (Grant Macarthur and Roger Lo)
40. Screening
Week 12
Initial increase in
total tumour burden
(mWHO PD)
Week 16
Responding
Week 96
Durable and ongoing response
without signs of irAEs
Εκτίμηση ανταπόκρισης
στην ανοσοθεραπεία
44. Αλληλουχία θεραπειών στους BRAFmut
• http//clinicaltrials.gov, NCT02224781
• Randomized phase III, NCI sponsored trial
Dabrafenib + Trametinib Followed by Ipilimumab +
Nivolumab OR Ipilimumab + Nivolumab Followed by
Dabrafenib + Trametinib in treating Patients with
stage III-IV BRAFV600 Melanoma